Search

Your search keyword '"Khan, Feroz"' showing total 903 results
Start Over Author "Khan, Feroz"
903 results on '"Khan, Feroz"'

4. Optimal Selection of Sustainable Energy Mix to Achieve Energy Security in Italy: A Fuzzy SWOT Approach

Author

Khan, Feroz, Rapposelli, Agnese, Spagnoletti, Paolo, Series Editor, De Marco, Marco, Series Editor, Pouloudi, Nancy, Series Editor, Te'eni, Dov, Series Editor, vom Brocke, Jan, Series Editor, Winter, Robert, Series Editor, Baskerville, Richard, Series Editor, Za, Stefano, Series Editor, Braccini, Alessio Maria, Series Editor, Lazazzara, Alessandra, editor, and Reina, Rocco, editor

Published
2024
Full Text
View/download PDF

5. Tackling nuclear terrorism in South Asia

Author

Khan, Feroz Hassan, BrigGen, Ret and Burke, Emily

Subjects
ASIA, SOUTHEASTERN - Security Measures, COUNTERTERRORISM - Asia, Southeastern, SECURITY, INTERNATIONAL, NUCLEAR WEAPONS - International Control
Abstract

illus tab bibliog

Published
2014

6. Minimum deterrence: Pakistan's dilemma

Author

Khan, Feroz Hassan

Subjects
NUCLEAR WEAPONS - Pakistan, DOCTRINE - Armed Forces - Pakistan, DETERRENCE, STRATEGY - Pakistan
Abstract

illus bibliog

Published
2011

31. Bridging fungal resistance and plant growth through constitutive overexpression ofThchit42gene inPelargonium graveolens

Author

Khatoon, Kahkashan, primary, Warsi, Zafar Iqbal, additional, Singh, Akanksha, additional, Singh, Kajal, additional, Khan, Feroz, additional, Singh, Palak, additional, Shukla, Rakesh Kumar, additional, Verma, Ram Swaroop, additional, Singh, Munmun K., additional, Verma, Sanjeet K., additional, Husain, Zakir, additional, Parween, Gazala, additional, Singh, Pooja, additional, Afroz, Shama, additional, and Rahman, Laiq Ur, additional

Published
2024
Full Text
View/download PDF

34. Extended Multitarget Pharmacology of Anticancer Drugs

Author

Shi, Da, Khan, Feroz, and Abagyan, Ruben

Subjects
Medicinal and Biomolecular Chemistry, Chemical Sciences, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Antineoplastic Agents, Databases, Pharmaceutical, Drug Approval, Drug Discovery, Internet, Molecular Dynamics Simulation, Molecular Targeted Therapy, Protein Conformation, Protein Kinase Inhibitors, Theoretical and Computational Chemistry, Computation Theory and Mathematics, Medicinal & Biomolecular Chemistry, Medicinal and biomolecular chemistry, Theoretical and computational chemistry
Abstract

Multitarget pharmacology of small-molecule cancer drugs significantly contributes to their mechanism of action, side effects, and emergence of drug resistance and opens ways to repurpose, combine, or customize drug therapy. In most cases, the set of targets affected at therapeutic concentrations is not fully characterized and/or the interaction efficacy values are not accurately quantified. We collected information about multiple targets for each cancer drug along with their experimental effective concentrations or binding activities from multiple sources. All multitarget activity values for each drug then were used to build two proximity network pharmacology maps of anticancer drugs and targets of those drugs, respectively. Together with the network map, we showed that the majority of the cancer drugs had substantial multitarget pharmacology based on our current knowledge. In addition, most of the cancer drugs simultaneously affect macromolecular targets from different classes and types. The target subset can further be accentuated and personalized by patient sample-specific expression data. The network maps of cancer drugs and targets as well as all quantified activity data were integrated into a freely available database, CancerDrugMap (http://ruben.ucsd.edu/dnet/maps/drugnet.html). The identified multitarget pharmacology of cancer drugs is essential for improving the efficacy of individually prescribed drugs and drug combinations and minimization of adverse effects.

Published
2019

38. Evaluation of Phytochemicals for Anti‐Tubercular Potential Targeting Enoyl‐Acyl Carrier Protein Reductase (InhA): An In Silico Approach.

Author

Gupta, Poonam, Sarfraz, Aqib, Yadav, Jyoti, Singh, Palak, and Khan, Feroz

Subjects
MYCOBACTERIUM tuberculosis, BINDING energy, MOLECULAR dynamics, CARRIER proteins, MOLECULAR docking
Abstract

Tuberculosis (TB) caused by the Mycobacterium tuberculosis (MTB) pathogen is a serious contagious illness that endangers the public's health. However, TB is treatable but due to the result of ineffective and protracted medication, MDR‐MTB and XDR‐MTB were able to develop, making their eradication highly challenging and necessitating potential treatments to be cured. This study aimed to identify the novel inhibitor for the InhA enzyme, a potential target of MTB. Initially, 2721 phytochemicals libraries were screened for ADME/Tox profiling and 49 phytochemicals were filtered out. Moreover, these phytochemicals with reference inhibitor triclosan were docked against InhA (PDB ID: 1BVR)., were showing binding energies ranging from −9.16–−6.3 kcal/mol, whereas triclosan showed −6.90 kcal/mol of binding energy. The docking results reveal that irilone (−9.16 kcal/mol) and aurantio‐obtusin (−8.84 kcal/mol) exhibit promising binding energy and perfectly occupy the binding site of InhA. Furthermore, molecular dynamics simulation (MDS) and MMGBSA studies showed better affinities of selected compounds in terms of stability, compactness, flexibility, and total BFE in complexes with InhA. This study concluded that irilone and aurantio‐obtusin could be promising InhA inhibitors based on their impressive pharmacokinetic profiling, toxicity, binding affinity, and stability. However experimental validation is a subject of further research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results